Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR-2: Adjuvant sintilimab + bevacizumab after resection of ruptured hepatocellular carcinoma
ChiCTR2500112474Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Ruijin Hospital. Primary endpoint: Disease-free survival. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
sintilimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500112474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112474.